Savara, Inc. (SVRA) News
Filter SVRA News Items
SVRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SVRA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SVRA News From Around the Web
Below are the latest news stories about SAVARA INC that investors may wish to consider to help them evaluate SVRA as an investment opportunity.
Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the companyKey Insights Given the large stake in the stock by institutions, Savara's stock price might be vulnerable to their... |
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)LANGHORNE, Pa., December 18, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. |
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare ConferenceLANGHORNE, Pa., December 17, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference. |
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)Key Insights Using the 2 Stage Free Cash Flow to Equity, Savara fair value estimate is US$3.72 Current share price of... |
Savara Announces New Employment Inducement GrantLANGHORNE, Pa., November 22, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. |
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024LANGHORNE, Pa., November 22, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England. |
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug CandidateAnalyst Liisa Bayko also slashed Savara's price target |
Savara Announces Participation in Upcoming Healthcare ConferencesLANGHORNE, Pa., November 13, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats. |
Savara Reports Third Quarter 2024 Financial Results and Provides Business UpdateLANGHORNE, Pa., November 12, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update. |
Savara to Present at the Guggenheim Inaugural Healthcare Innovation ConferenceLANGHORNE, Pa., November 04, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be available on Savara's website at https://savarapharma.com/investors/events-presentations/ and will be a |